PolyPeptide Group AGPLYGF 56 Days Inventory is 164.20 as of Dec. 2025, which is 16% below its 10-year median of 195.49. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $26.83 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 916 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 52.73% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
PolyPeptide Group AG's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.11.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PolyPeptide Group AG's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.69.
PolyPeptide Group AG (OTCPK:PLYGF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
PolyPeptide Group AG's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PolyPeptide Group AG's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
PolyPeptide Group AG Days Inventory Related Terms
PolyPeptide Group AG Days Inventory Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLYGF vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Days Inventory distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a Days Inventory of 164.20 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on PolyPeptide Group AG and its competitors. This is 16% below median its historical median of 195.49. Over the past decade, PolyPeptide Group AG's Days Inventory has ranged from 162.03 to 224.79. According to the industry distribution chart, PolyPeptide Group AG ranks #483 out of 916 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is PolyPeptide Group AG's Days Inventory too high?
PolyPeptide Group AG's current Days Inventory of 164.20 is 16% below median its 10-year median of 195.49. Over the past 10 years, this metric has ranged from a low of 162.03 to a high of 224.79. The Drug Manufacturers industry median Days Inventory is 164.43. PolyPeptide Group AG's value of 164.20 is 0.1% below this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #483 out of 916 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #483 out of 916 companies for Days Inventory. This places PolyPeptide Group AG in the lower half of its industry. The industry median Days Inventory is 164.43. PolyPeptide Group AG's value of 164.20 is 0.1% below this benchmark. Historically, PolyPeptide Group AG's own Days Inventory has ranged from 162.03 to 224.79 over the past decade. While the company's 10-year median is 195.49 vs. the industry median of 164.43, PolyPeptide Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Days Inventory of 164.20 is 0.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Days Inventory is 164.20, which is 16% below median its own 10-year median of 195.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current Days Inventory is 164.20, which is 16% below median its 10-year median of 195.49 and 0.1% below the Drug Manufacturers industry median of 164.43. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Days Inventory is 164.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
Days Inventory: 164.20 (16% below median its 10-year median of 195.49)
GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
Industry Position: 0.1% below the Drug Manufacturers median (#483 of 916)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score
Get the complete analysis for PLYGF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
